Skip to main content

What to Know About TB4 and TB-500 Peptide Therapy

Can these peptides really promote better healing, organ regeneration, and hair growth?

by
Last updated: Mar 28th, 2025
Innerbody is independent and reader-supported. When you buy through links on our site, we will earn commission.   .
TB-500 peptide

Photo by Innerbody Research

If you’re reading this guide, chances are you’ve heard something about peptide therapy. Though a few FDA-approved options are already on the market — like semaglutide (Ozempic; for diabetes) and bremelanotide (Vyleesi; for hypoactive sexual desire disorder) — other peptides in various states of approval have been growing in popularity. Despite many of them still being in the preclinical phase of testing, some doctors have been prescribing these potentially beneficial peptides for years.

Two of those peptides, thymosin beta-4 (TB4) and TB-500, are touted as being able to promote a wide range of health benefits, some of which include faster injury recovery, lower inflammation, better heart health, and even increased hair growth. In this guide, we’ll explore the legitimacy of these claims, address questions about safety, and offer an inside look at the patient experience.

Jump to

Jump to:

Why you should trust us

Over the past two decades, Innerbody Research has helped tens of millions of readers make more informed decisions about staying healthy and living healthier lifestyles.

Our team has dedicated hundreds of hours over the years researching various peptides, two of which are TB4 and one of its synthetic analogs, TB-500. Through lengthy research, communicating with credible doctors, and gaining firsthand knowledge from one of our own team members, we’ve learned key details about TB4 and TB-500’s safety, potential benefits, bioavailability, efficacy, patient use experience, and much more.

Additionally, like all health-related content on this website, this review was thoroughly vetted by one or more members of our Medical Review Board for accuracy. As the research on peptides evolves, so will the information in this guide.

What are TB4 and TB-500?

Simply put, TB-500 (or fequesetide) is a synthetic peptide based on a segment of the naturally occurring peptide thymosin beta-4 (often written as Tβ4 or TB4). While TB4 is made up of 43 amino acids, TB-500 only contains seven. Sometimes, especially in earlier research, you may see TB-500 referred to by its amino acid sequence, Ac-LKKTETQ.

Insider Tip: The “Ac-” before amino acid sequences, like those of peptides, means it’s been permanently modified with an added acetyl group — a process called N-terminal acetylation — to protect it from degradation. This can improve a peptide’s stability, bioavailability, and other properties. Though nearly all synthetic peptides are protected in one way or another during synthesis, this protection is usually reversible; not every synthetic peptide is permanently acetylated.

Thymosins are a type of hormone-like polypeptide produced by the thymus, a small gland located behind your sternum that makes most of your body’s T lymphocytes (white blood cells that help your immune system function properly to destroy things like pathogens or even cancer cells). Though there are multiple distinct thymosins, TB4 (thymosin beta-4) is, according to researchers, “the most abundant and biologically active member of the family in most mammalian cells…” In humans, TB4 is present in high concentrations in “all tissue types except red blood cells, with highest levels occurring in platelets, white blood cells, plasma, and wound fluid.”

TB4 is an important actin-binding protein that helps actin perform various functions, such as muscular contraction and maintaining proper cell shape, movement, and division. These effects on cells are why some experts suggest supplemental TB4 can improve the repair and recovery of muscle and other soft tissues, promote wound healing, reduce inflammation, and more. Researchers also note that TB4 is “critical” for the repair and regeneration of eye, heart, skin, nerve, and brain tissue after injury.

Pivoting to TB-500, it’s based on a single one of the “active sites” of TB4 — the peptide segment responsible for the compound’s actin-binding and cell migration abilities. Since most of TB4’s potential benefits are attributed to its actin-binding properties, it can be assumed that the same applies to TB-500. However, that is mainly an assumption at this point in time, as there isn’t very much research on TB-500 itself; most of it focuses on TB4.

Insider Tip: Unfortunately, peptides aren’t typically very bioavailable (even when administered intravenously or subcutaneously) but TB-500 may have improved bioavailability over TB4 due to its smaller size and stabilizing N-terminal acetylation.

What are TB4 and TB-500 peptides used for?

Though these peptides may be able to support various aspects of your body’s general health and wellness based on current research, they’re most often promoted as ways to:

  • Repair or regenerate tissue (e.g., heal injuries, boost muscle recovery)
  • Lower inflammation
  • Promote blood vessel formation
  • Protect certain organs (e.g., heart, liver, and eyes)

The above potential benefits also have some of the most promising research. However, it’s important to keep in mind that the majority of the data on TB4 (and TB-500) thus far is from preclinical studies done on cells or animal subjects. Below, we break down the details from a few notable pieces of research, including the outcomes of a few completed clinical (human) trials.

February 2003 study

A 2003 mouse study found that TB4 in a solution or gel form promoted accelerated wound healing in healthy, diabetic, and aged mice. Researchers also point out that a “seven-amino acid synthetic peptide” based on the actin-binding part of TB4 was “able to promote repair in the aged animals comparable to that observed with the parent molecule.” The amino acid sequence noted is LKKTETQ — or TB-500 without the N-terminal acetylation.

November 2011 review

In a review of TB4’s basic properties and clinical applications, researchers dub it a “regenerative peptide” due to its role in repairing injured cells and tissues. After an injury, the body releases TB4, which works to reduce inflammation and “protect cells and tissues from further damage.” The authors go on to explain that TB4’s tissue regeneration ability is partially due to it promoting the formation of new blood vessels (angiogenesis). And, since TB4 “decreases the number of myofibroblasts in wounds,” scarring after an injury is less likely to occur.

July 2018 study

A 2018 study on mice found that TB4 — due to its apparent ability to reduce inflammation, oxidative stress, and the formation of fibrosis (scar tissue) — may be able to improve health outcomes in those with alcoholic liver injury.

May 2021 review

In this 2021 review, researchers suggest that, since TB4 is “critical during embryonic development,” it may be a candidate for future therapies focused on reversing physical aging. This is because injections of TB4 into the hearts of mice (both injured and uninjured) basically kickstarted repair processes and made the epicardium (the outermost layer of the heart) behave as it does in embryonic development. Thus, the authors state that TB4 may be “capable of re-activating embryonic processes.”

December 2021 review

This review covers the results of a few human TB4 trials. One trial evaluated TB4 for heart health, finding that the peptide could “protect and repair” the heart in patients with acute myocardial infarction. And a separate trial found that TB4 improved outcomes during congenital heart surgery.

The review also mentions a few clinical trials related to eye health, with results showing that TB4 can reduce eye dryness, relieve ocular discomfort, lower inflammation in the conjunctiva, and more. Finally, the review notes that a couple of clinical studies on TB4 for wound healing both resulted in the peptide accelerating the healing process.

March 2024 study

Interestingly, in this study, researchers found that TB-500 (Ac-LKKTETQ) didn’t increase wound healing activity, but one of its metabolites — Ac-LKKTE — did. This suggests that, as the authors explain, the “reported wound-healing activity of TB-500 in literature may be due to its metabolite Ac-LKKTE rather than the parent form.”

Additionally, there have been some positive preclinical research outcomes for the use of TB4 for hair growth, neuroprotection, tympanic membrane perforations, and decreasing mortality in sepsis, but more clinical research is needed before these potential benefits can be considered applicable to humans.

Are TB4 and TB-500 safe?

Based on current research, TB4 appears to be generally safe for adults when used as directed under the supervision of a medical professional. Unfortunately, however, there aren’t any studies on the safety of TB-500, its synthetic analog. Even though TB-500 is based on a part of TB4, its safety can’t necessarily be assumed; studies analyzing the safety of the peptide still need to be conducted.

With that being said, TB4 has been safely used in a number of preclinical and clinical trials. Some notable safety-related quotes from scientific materials include:

  • A 2016 review of TB4 for dermal healing: “The safety profile is excellent, and no preclinical toxicology has been found.”
  • A 2016 clinical trial on patients with STEMI: “Our pilot study suggested that Tβ4-optimized EPC transplantation appeared to be feasible and safe…”
  • A 2021 review of TB4 research: “It was well tolerated and safe in healthy people and suitable for use in a clinical study…”

Though the compound itself may be generally safe for adults to use, some common side effects from TB4 injections reported by patients and doctors include:

  • Injection site reactions (e.g., redness, mild swelling, or pain)
  • Mild gastrointestinal symptoms
  • Headaches and dizziness

Rare but more serious side effects can include fever, blistering at the injection site, muscle aches, skin rash, vomiting, severe itching, or hives. If these occur, it’s recommended to stop using the peptide and contact your doctor.

Insider Tip: Despite being available on the market, research-grade peptides are not suitable for use in humans due to their lower purity standards. Only medical- or pharmaceutical-grade peptides prescribed by a qualified physician should be used for therapy.

Finally, it’s important to note that it’d be unsafe for certain groups of people to use TB4 or TB-500, including those who are pregnant or breastfeeding and those who have suspected or active cancer. These peptides haven’t been evaluated in pregnant or breastfeeding individuals, so their safety hasn’t been established. And, since TB4 and TB-500 can stimulate the growth of new blood vessels (angiogenesis), they may support the spread or growth of cancer. A physician can order any and all necessary pre-treatment tests as a prerequisite for prescribing peptide therapy.

Who could TB-500 or TB4 peptide therapy be suitable for?

Currently, it seems like TB4 and TB-500 could be best suited for adults with troublesome injuries or wounds (including those that are slow to heal), inflammation, chronic pain due to inflammation, or health issues involving the heart, liver, or eyes. But, it’s essential to remember that the research on these peptides is still in the early stages, and there have only been a handful of human trials. While those trials were largely successful, more research is needed to confirm the potential benefits of supplemental TB4 or TB-500.

Who should avoid TB4 and TB-500 peptides?

Until more research is conducted, we don’t know all of the populations that should avoid TB4 and TB-500. There could be undiscovered medication interactions or reactions with certain medical conditions (which is one of many reasons why we highly recommend only using these peptides under the guidance of a doctor).

From what we do know, the three groups that should avoid TB4 and TB-500 include:

  • Those who are pregnant or breastfeeding: The safety of these peptides hasn’t been established in pregnant or nursing individuals.
  • People with cancer (active or suspected): As mentioned previously, TB4 and TB-500 can promote the growth of new blood vessels, which could support the growth or spread of cancer.
  • Professional athletes: TB4 and TB-500 are banned by The World Anti-Doping Agency (WADA); the peptides fall under the ban on “Peptide Hormones, Growth Factors, Related Substances, and Mimetics.”

What’s it like to use TB4 or TB-500?

From our research — including speaking with knowledgeable health professionals and having a team member with firsthand experience — we can share a few insights into what it’s like to use TB4 or TB-500 peptide therapy.

Since peptides' oral bioavailability is particularly limited, they are often administered by injection into subcutaneous fat (stomach, thighs, or upper arms). The TB4 or TB-500 injections can be used at any time of day, once per day, for five days per week followed by two days off. If using these peptides long term, you’ll likely cycle them, with one month off for every three months of use (or three cycles per year).

Insider Tip: Some reputable clinics offer a combination peptide therapy containing TB4 and BPC-157, or Body Protection Compound 157. These peptides can work well together to promote better healing and recovery. For example, while TB4 boosts cellular migration to injuries, BPC-157 can protect and regenerate soft tissues.

Initial improvements are often mild and include things like lower inflammation or increased mobility in injured areas. After around a month or two, patients may notice more significant changes, such as faster healing and recovery times. With long-term use, scarring from injuries might decrease, cardiovascular improvements can be more noticeable, and sustained improvements in overall physical recovery may occur.

Insider Tip: Like many other prescription or supplemental products, peptides should generally be stored in a cool, dry, dark place to prevent degradation. Keeping them in the fridge may be an ideal solution. Consult with your prescribing doctor or any included materials for guidance on storage.

Common side effects from the injections may include symptoms like injection site irritation, gastrointestinal discomfort, headaches, and dizziness, but they tend to be mild and transient. More rarely, a patient may experience severe symptoms like a fever of 100.4°F (38°C) or higher, injection site blistering, muscle pain, skin rashes, hives, severe skin itching, or vomiting. In those cases, it’s best to discontinue using the peptide and reach out to your prescribing physician.

Some advice to reduce side effects from physicians well-versed in peptide therapy include:

  • Start off with a lower dose and increase to the prescribed dose gradually
  • Change up your injection sites to reduce irritation and prevent localized swelling
  • Try taking your peptides along with food if gastrointestinal symptoms occur
  • Maintain proper hydration to support your body throughout therapy
  • Keep in touch with your prescribing physician; they can make adjustments to your treatment and monitor your health status throughout

Guidance on obtaining TB4 and TB-500 peptides

A quick search on the internet for TB4 or TB-500 will often present you with a host of online sellers, many of which aren’t exactly trustworthy and may try to sell customers research-grade peptides instead of pharmaceutical- or medical-grade ones. Though both research- and medical/pharmaceutical-grade peptides are on the market, only the latter would be suitable for humans; research-grade peptides are not safe for human use. As noted in one study, the purity criteria for research-grade materials are “generally much less rigorous, partially incomplete, and/or poorly followed.” This could mean injecting yourself with unknown contaminants.

The above information is one of the many reasons why it’s essential to only get your peptides through a qualified medical doctor, either through a reputable in-person clinic or telehealth service.

38

Sources

Innerbody uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

  1. Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022). Therapeutic peptides: Current applications and future directions. Signal Transduction and Targeted Therapy, 7(1), 1-27.

  2. Kingsberg, S. A., Clayton, A. H., Portman, D., Williams, L. A., Krop, J., Jordan, R., Lucas, J., & Simon, J. A. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology, 134(5), 899.

  3. National Center for Biotechnology Information. (2025). PubChem Compound Summary for CID 10169788, Fequesetide. National Library of Medicine.

  4. Ho, E. N., Kwok, W., Lau, M., Wong, A. S., Wan, T. S., Lam, K. K., Schiff, P. J., & Stewart, B. D. (2012). Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry. Journal of Chromatography A, 1265, 57-69.

  5. Belsky, J. B., Rivers, E. P., Filbin, M. R., Lee, P. J., & Morris, D. C. (2018). Thymosin beta 4 regulation of actin in sepsis. Expert Opinion on Biological Therapy, 18(SUP1), 193.

  6. The Global Substance Registration System (GSRS). (n.d.). TB-500. National Institutes of Health.

  7. Ree, R., Varland, S., & Arnesen, T. (2018). Spotlight on protein N-terminal acetylation. Experimental & Molecular Medicine, 50(7), 1-13.

  8. McTiernan, N., Kjosås, I., & Arnesen, T. (2025). Illuminating the impact of N-terminal acetylation: From protein to physiology. Nature Communications, 16(1), 1-15.

  9. Li, D., Yang, Y., Li, R., Huang, L., Wang, Z., Deng, Q., & Dong, S. (2021). N-terminal acetylation of antimicrobial peptide L163 improves its stability against protease degradation. Journal of peptide science: an official publication of the European Peptide Society, 27(9), e3337.

  10. John, H., Maronde, E., Forssmann, W. G., Meyer, M., & Adermann, K. (2008). N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity. European journal of medical research, 13(2), 73–78.

  11. Marciano, Y., Nayeem, N., Dave, D., Ulijn, R. V., & Contel, M. (2023). N-Acetylation of Biodegradable Supramolecular Peptide Nanofilaments Selectively Enhances their Proteolytic Stability for Targeted Delivery of Gold-Based Anticancer Agents. ACS Biomaterials Science & Engineering, 9(6), 3379.

  12. Stawikowski, M., & Fields, G. B. (2002). Introduction to Peptide Synthesis. Current Protocols in Protein Science / Editorial Board, John E. Coligan ... [et al.], CHAPTER, Unit.

  13. Conda-Sheridan, M., & Krishnaiah, M. (2020). Protecting Groups in Peptide Synthesis. Methods in molecular biology (Clifton, N.J.), 2103, 111–128.

  14. Severa, M., Zhang, J., Giacomini, E., Rizzo, F., Etna, M. P., Cruciani, M., Garaci, E., Chopp, M., & Coccia, E. M. (2019). Thymosins in multiple sclerosis and its experimental models: Moving from basic to clinical application. Multiple Sclerosis and Related Disorders, 27, 52-60.

  15. Cleveland Clinic. (2022). Thymus. Cleveland Clinic.

  16. Cleveland Clinic. (2023). T Cells. Cleveland Clinic.

  17. Sosne, G., Rimmer, D., Kleinman, H., & Ousler, G. (2016). Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases. Vitamins and Hormones, 102, 277-306.

  18. National Cancer Institute. (n.d.). Recombinant thymosin. NIH.

  19. Dominguez, R., & Holmes, K. C. (2011). Actin Structure and Function. Annual Review of Biophysics, 40, 169.

  20. Spurney, C. F., Cha, J., Sali, A., Pandey, G. S., Pistilli, E., Guerron, A. D., Gordish-Dressman, H., Hoffman, E. P., & Nagaraju, K. (2010). Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse. PLoS ONE, 5(1), e8976.

  21. Xing, Y., Ye, Y., Zuo, H., & Li, Y. (2021). Progress on the Function and Application of Thymosin β4. Frontiers in Endocrinology, 12, 767785.

  22. Kleinman, H., & Sosne, G. (2016). Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 102, 251-275.

  23. Sosne, G., Qiu, P., & Kurpakus-Wheater, M. (2007). Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. Clinical Ophthalmology (Auckland, N.Z.), 1(3), 201.

  24. Bruno, B. J., Miller, G. D., & Lim, C. S. (2013). Basics and recent advances in peptide and protein drug delivery. Therapeutic Delivery, 4(11), 1443.

  25. Lamers, C. (2022). Overcoming the Shortcomings of Peptide-Based Therapeutics. Future Drug Discovery, 4(2), FDD75.

  26. Philp, D., Badamchian, M., Scheremeta, B., Nguyen, M., Goldstein, A. L., & Kleinman, H. K. (2003). Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration, 11(1), 19-24.

  27. Goldstein, A. L., Hannappel, E., Sosne, G., & Kleinman, H. K. (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert opinion on biological therapy, 12(1), 37–51.

  28. Shah, R., Reyes-Gordillo, K., Cheng, Y., Varatharajalu, R., Ibrahim, J., & Lakshman, M. R. (2018). Thymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Ethanol- and LPS-Induced Liver Injury in Mice. Oxidative Medicine and Cellular Longevity, 2018(1), 9630175.

  29. Maar, K., Hetenyi, R., Maar, S., Faskerti, G., Hanna, D., Lippai, B., Takatsy, A., & Bock-Marquette, I. (2021). Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State—New Directions in Anti-Aging Regenerative Therapies. Cells, 10(6), 1343.

  30. Rahaman, K. A., Muresan, A. R., Min, H., Son, J., Han, H., Kang, M., & Kwon, O. (2024). Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography B, 1235, 124033.

  31. Gao, X., Liang, H., Hou, F., Zhang, Z., Nuo, M., Guo, X., & Liu, D. (2015). Thymosin Beta-4 Induces Mouse Hair Growth. PLoS ONE, 10(6), e0130040.

  32. Song, K., Han, H., Kim, S., & Kwon, J. (2020). Thymosin beta 4 attenuates PrP(106-126)-induced human brain endothelial cells dysfunction. European Journal of Pharmacology, 869, 172891.

  33. Bako, P., Lippai, B., Nagy, J., Kramer, S., Kaszas, B., Tornoczki, T., & Bock-Marquette, I. (2023). Thymosin beta-4 – A potential tool in healing middle ear lesions in adult mammals. International Immunopharmacology, 116, 109830.

  34. Zhu, J., Song, J., Yu, L., Zheng, H., Zhou, B., Weng, S., & Fu, G. (2016). Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST-segment elevation myocardial infarction: A pilot study. Cytotherapy, 18(8), 1037–1042.

  35. Pauli, G. F., Chen, N., Simmler, C., Lankin, D. C., Gödecke, T., Jaki, B. U., Friesen, J. B., McAlpine, J. B., & Napolitano, J. G. (2014). Importance of Purity Evaluation and the Potential of Quantitative 1H NMR as a Purity Assay: Miniperspective. Journal of Medicinal Chemistry, 57(22), 9220.

  36. Johns Hopkins. (n.d.). Angiogenesis Inhibitors. Johns Hopkins Medicine.

  37. The World Anti-Doping Agency. (2024). 2025 World Anti-Doping Code International Standard Prohibited List. WADA.

  38. Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and tissue research, 377(2), 153–159.